Abeona price target raised to $25 from $20 at Alliance Global Partners

Alliance Global Partners raised the firm’s price target on Abeona Therapeutics (ABEO) to $25 from $20 and keeps a Buy rating on the shares after the company reported Q4 results and highlighted ongoing pre-approval efforts for lead prademagene zamikeracel gene therapy for recessive dystrophic epidermolysis bullosa. The firm values pz-cel for RDEB at $21 per share, the potential Priority Review Voucher for pz-cel at $3 per share, and the remaining pipeline at $1 per share, the analyst noted.